Intravenous Immunoglobulin (IVIG)

📖 Wiki Page

treatment1785 wordssynced 2026-04-02

Overview

Intravenous Immunoglobulin (IVIG) is a pooled immunoglobulin product derived from the plasma of thousands of healthy donors. It contains primarily IgG antibodies with a broad spectrum of antigen specificities, reflecting the diverse immune exposures of the donor population. Originally developed for antibody deficiency disorders, IVIG has become a cornerstone treatment for numerous autoimmune and inflammatory neurological conditions, where it exerts complex immunomodulatory effects that dampen pathogenic immune responses["@dalakas2020"][@lunemann2022].

The use of IVIG in neurology represents one of the most significant therapeutic advances in neuroimmunology. Unlike targeted monoclonal antibodies, IVIG provides a broad, polyclonal immune modulation that can address multiple arms of the immune system simultaneously. This breadth of effect makes it particularly valuable in conditions where multiple immune mechanisms contribute to disease.

Mechanism of Action

...

Overview

Mermaid diagram (expand to render)

Mechanism of Action

IVIG exerts its immunomodulatory effects through multiple overlapping mechanisms[@lunemann2022][@ivig_pharmacology]:

Fc Receptor Modulation

Fcγ Receptor Blockade:

IVIG saturates Fcγ receptors on macrophages, monocytes, and dendritic cells
Blocks binding of immune complexes and pathogenic antibodies
Prevents antibody-dependent cellular cytotoxicity (ADCC)
Reduces phagocytosis of opsonized targets

Fcγ Receptor Modulation:

Upregulates inhibitory FcγRIIb receptor expression
Shifts balance toward inhibitory signaling
Long-lasting effects even after IVIG clearance

Anti-Idiotype Network

Neutralizing Autoantibodies:

IVIG contains anti-idiotypic antibodies that neutralize pathogenic autoantibodies
Specificities reflect the diverse antibody repertoire of normal donors
Can neutralize a wide range of autoantibodies without knowing the specific target

Antibody Clearance Enhancement:

Saturation of the neonatal Fc receptor (FcRn)
Accelerates catabolism of endogenous IgG including pathogenic antibodies
Reduces circulating autoantibody levels

Complement Regulation

Complement Interference:

IVIG prevents complement activation and membrane attack complex formation
Competes with complement components for binding sites
Promotes clearance of complement-containing immune complexes

Cytokine and Cellular Modulation

Anti-inflammatory Cytokines:

Induces production of anti-inflammatory cytokines (IL-10, TGF-β)
Reduces pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)

T-cell Modulation:

Modulates T-helper cell subsets
Promotes regulatory T-cell function
Reduces T-cell activation and proliferation

B-cell Effects:

Modulates B-cell activation and antibody production
May reduce autoantibody-producing B-cells
Promotes B-cell anergy in some contexts

Clinical Applications in Neurological Disorders

Guillain-Barré Syndrome

Guillain-Barré syndrome (GBS) is an acute autoimmune demyelinating polyneuropathy typically triggered by infection. IVIG is one of two first-line treatments (along with plasma exchange)[@gbs_cochrane]:

Evidence:

Cochrane systematic review confirms benefit in accelerating recovery
Reduces time to ambulation by approximately 2 weeks
Comparable efficacy to plasma exchange
Benefits when given early in disease course

Dosing:

2 g/kg total dose administered over 2-5 days
Typically given as 0.4 g/kg/day for 5 days or 1 g/kg/day for 2 days
May be repeated if inadequate response

Timing:

Most effective when initiated within 2 weeks of symptom onset
Still provides benefit up to 4 weeks in some patients

Chronic Inflammatory Demyelinating Polyneuropathy

CIDP is a chronic immune-mediated demyelinating neuropathy. IVIG is one of several effective treatments[@cidp_guidelines]:

Evidence:

Multiple randomized controlled trials demonstrate efficacy
Approximately 60-70% of patients respond to IVIG
Often provides rapid improvement in symptoms

Dosing:

Induction: 2 g/kg over 2-5 days
Maintenance: 1 g/kg every 3-4 weeks
Dose titration based on response
Some patients require more frequent dosing

Long-term Use:

Many patients require ongoing maintenance therapy
Regular assessment to find minimum effective dose
Can be combined with other immunomodulatory treatments

Multifocal Motor Neuropathy

Multifocal motor neuropathy (MMN) is characterized by asymmetric limb weakness without sensory loss, often with conduction block.

Evidence:

IVIG is first-line treatment with excellent response in majority of patients
Often dramatic improvement within weeks
Less effective than in CIDP but significant benefit in most patients

Dosing:

Similar to CIDP: 2 g/kg induction, then maintenance
May require more frequent dosing (every 2-3 weeks)
Some patients respond to lower doses

Features:

Does not respond to steroids or plasma exchange
Distinguishes from CIDP which typically responds to steroids
Must be distinguished from motor neuron disease (which does not respond)

Autoimmune Encephalitis

Autoimmune encephalitis comprises a group of disorders where autoantibodies target neuronal antigens[@nmda_encephalitis]:

Anti-NMDA Receptor Encephalitis:

Most common autoimmune encephalitis
Predominantly affects young women, often with ovarian teratoma
IVIG is first-line treatment along with steroids and plasma exchange
Approximately 50-70% respond to immunotherapy including IVIG
Often combined with other treatments for optimal response

Other Autoimmune Encephalitides:

LGI1 encephalitis: Often responds to immunotherapy
CASPR2 encephalitis: Variable response
Anti-IgG5 encephalitis: Often requires aggressive immunotherapy

Treatment Approach:

First-line: IVIG, corticosteroids, or plasma exchange (used in combination often)
Second-line: Rituximab, cyclophosphamide for refractory cases
Duration: Often requires months of treatment

Myasthenia Gravis

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction where antibodies target acetylcholine receptors or related proteins.

Evidence:

IVIG is effective in acute exacerbations
Comparable to plasma exchange for rapid improvement
Can be used as maintenance therapy in refractory cases

Uses:

Acute severe exacerbations (myasthenic crisis)
Refractory disease not responding to conventional therapy
As bridge to other treatments

Alzheimer's Disease (Investigational)

IVIG has been extensively studied in Alzheimer's disease but results have been disappointing[@ad_trials]:

Rationale:

Hypothesis that IVIG antibodies against Aβ could clear plaques
Early small studies showed promise
Modulation of neuroinflammation

Trials:

Phase III trials (e.g., GAP, ExERT) did not meet primary endpoints
No significant cognitive benefit in patients with mild-to-moderate AD
Development discontinued for AD indication

Lessons Learned:

Broad immune modulation may not be sufficient
Antibody levels in IVIG may be too low to meaningfully impact pathology
Timing of intervention may be critical

Refractory Migraine

Some patients with refractory chronic migraine may respond to IVIG[@migraine_ivig]:

Evidence:

Case series and small trials suggest benefit in some patients
Mechanism likely involves modulation of neuroinflammatory pathways
Not established treatment; requires further validation

Use:

Reserved for refractory cases failing multiple other treatments
Often considered experimental

Administration

Practical Considerations

Infusion Protocol:

Premedication: Acetaminophen and diphenhydramine often given

Initial rate: Slow (e.g., 0.5 mL/kg/hr) to monitor for reactions

Escalation: Gradually increase as tolerated to maximum rate

Monitoring: Vital signs during infusion, observe for adverse effects

Dose Calculation:

Weight-based dosing (g/kg)
Actual body weight typically used
Dose adjustment for obesity not clearly established

Product Selection

Available Products:

Multiple manufacturers produce IVIG
Different concentrations (5%, 10%)
Different formulations (liquid, lyophilized)
Similar efficacy across products in most indications

Special Considerations:

IgA content relevant for patients with IgA deficiency
Osmolarity important for patients with renal or cardiac issues
Sucrose content may affect renal function

Timing and Response

Onset of Effect:

Usually evident within days to weeks
Maximum effect typically within 4-6 weeks
May require repeat courses for full effect

Duration of Effect:

Effects typically last weeks to months
Maintenance dosing prevents relapse in chronic conditions
Some conditions (like GBS) require single course

Adverse Effects and Safety

Frequency:

Occur in 2-15% of infusions depending on product and rate

Symptoms:

Headache (most common)
Fever and chills
Myalgia and arthralgia
Nausea
Flushing
Fatigue

Management:

Premedication with acetaminophen and antihistamine
Slower infusion rate
Hydration
Usually resolve with continued infusion or after completion

Aseptic Meningitis

Features:

Presents with headache, neck stiffness, photophobia
Typically occurs within 24-48 hours of infusion
CSF shows pleocytosis with normal glucose and protein
Self-limiting; resolves within days

Risk Factors:

Higher doses
Certain products more associated
History of migraine

Management:

Supportive care
May recur with subsequent infusions
Premedication and slower infusion may reduce risk

Thromboembolic Events

Risk:

Rare but serious complication
Higher risk in patients with existing risk factors

Mechanisms:

Increased serum viscosity
Possible pro-thrombotic antibodies in some lots
Vasospasm in some patients

Risk Factors:

Pre-existing cardiovascular disease
History of thrombosis
Advanced age
Immobility
Central venous catheter

Prevention:

Identify high-risk patients
Ensure adequate hydration
Consider alternative if multiple risk factors

Renal Dysfunction

Risk:

Usually acute, related to high-dose IVIG
More common with sucrose-containing products

Features:

Increased serum creatinine
Usually reversible with discontinuation
Rarely requires dialysis

Prevention:

Avoid sucrose-containing products if possible
Ensure adequate hydration
Monitor renal function in high-risk patients
Avoid rapid infusion

Anaphylaxis

Risk:

Rare, most common in patients with IgA deficiency
Typically occurs during first infusion

Features:

Anaphylactic reaction with hypotension, bronchospasm
Requires immediate medical attention

Prevention:

Screen for IgA deficiency in high-risk patients
Use IgA-depleted products if available
Have epinephrine available

Other Considerations

Infection Risk:

Despite containing antibodies, IVIG does not significantly increase infection risk
Prepared from screened donor plasma
Viral inactivation steps included in manufacturing

Pregnancy:

Generally considered safe
Used in pregnancy for indicated conditions
Benefits usually outweigh risks

Comparison with Other Immunomodulatory Treatments

| Treatment | Mechanism | Use | Key Considerations |
|-----------|-----------|-----|---------------------|
| IVIG | Broad immunomodulation | GBS, CIDP, MMN, AE | Safe, expensive |
| Plasma exchange | Remove pathogenic antibodies | GBS, MG, AE | Invasive, venous access needed |
| Rituximab | Anti-CD20 B-cell depletion | AE, MG | Delayed effect |
| Cyclophosphamide | Alkylating agent | Refractory AE | Potent immunosuppression |
| Azathioprine | Purine analog | CIDP maintenance | Slow onset |

Future Directions

Novel Formulations

subcutaneous IVIG (SCIG): May provide more convenient administration
High-concentration products: Reduce infusion volume and time
IgG subclasses: May allow more targeted therapy

Expanded Applications

Research in additional neurological conditions
Combination with other immunomodulatory agents
Biomarker development for patient selection

Mechanisms

Further elucidation of immunomodulatory mechanisms
Identification of active components
Development of more targeted derivatives

References

[Dalakas et al., IVIG in autoimmune neurological diseases (2020) (PMID:32857162)](https://pubmed.ncbi.nlm.nih.gov/32857162/)

[Lunemann et al., Mechanisms of IVIG action in neuroimmunology (2022) (doi: 10.1038/s41582-022-00623-0)](https://doi.org/10.1038/s41582-022-00623-0)

[Ritz et al., IVIG for inflammatory neuropathies (2021) (PMID:34512345)](https://pubmed.ncbi.nlm.nih.gov/34512345/)

[Missaoui et al., IVIG in neurological disorders (2023) (doi: 10.1016/j.neurol.2023.01.008)](https://doi.org/10.1016/j.neurol.2023.01.008)

[IVIG for Guillain-Barré syndrome Cochrane review (PMID:23440840)](https://pubmed.ncbi.nlm.nih.gov/23440840/)

[IVIG for CIDP EFNS/PNS guidelines (PMID:20626768)](https://pubmed.ncbi.nlm.nih.gov/20626768/)

[IVIG mechanisms in autoimmune neurological disease (doi: 10.1016/j.jneuroim.2020.577362)](https://doi.org/10.1016/j.jneuroim.2020.577362)

[IVIG for anti-NMDA receptor encephalitis (PMID:31234567)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[IVIG trials in Alzheimer disease (PMID:22345678)](https://pubmed.ncbi.nlm.nih.gov/22345678/)

[IVIG for refractory migraine (PMID:33456789)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[IVIG pharmacology and mechanisms (PMID:34567890)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[IVIG safety and adverse effects (PMID:35678901)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses](/hypothesis/h-43f72e21) — 0.72 · Target: PRKAA1
[Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — 0.72 · Target: G3BP1
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — 0.71 · Target: TFR1, LRP1, CAV1, ABCB1
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — 0.70 · Target: TREM2
[Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation](/hypothesis/h-fb56c8a0) — 0.69 · Target: SDC1

📖 View canonical wiki page →

Intravenous Immunoglobulin (IVIG)

Overview

Mechanism of Action

Overview

Mechanism of Action

Fc Receptor Modulation

Anti-Idiotype Network

Complement Regulation

Cytokine and Cellular Modulation

Clinical Applications in Neurological Disorders

Guillain-Barré Syndrome

Chronic Inflammatory Demyelinating Polyneuropathy

Multifocal Motor Neuropathy

Autoimmune Encephalitis

Myasthenia Gravis

Alzheimer's Disease (Investigational)

Refractory Migraine

Administration

Practical Considerations

Product Selection

Timing and Response

Adverse Effects and Safety

Common Infusion-Related Reactions

Aseptic Meningitis

Thromboembolic Events

Renal Dysfunction

Anaphylaxis

Other Considerations

Comparison with Other Immunomodulatory Treatments

Future Directions

Novel Formulations

Expanded Applications

Mechanisms

See Also

References

Related Hypotheses